INSTITUTION CLINICAL TRIAL AGREEMENTInstitution Clinical Trial Agreement • October 5th, 2017
CHILTERN INTERNATIONAL s.r.o., Business Centrum Zalesi, Building A2, Pod Visnovkou 1661/31, 140 00 Praha 4 – Krc, Czech Republic, registered in the Commercial Register maintained by the Municipal Court in Prague, section C., Insert: 130938, identification number: 281 78 777, tax ID: CZ28178777, represented by executive manager, MUDr. Dariusz Walach, (hereinafter referred to as “Chiltern”); and
ContractInstitution Clinical Trial Agreement • March 12th, 2018
INSTITUTION CLINICAL TRIAL AGREEMENT This Clinical Trial Agreement (“Agreement”) is made on(“Effective Date”) byand among: CHILTERN INTERNATIONAL s.r.o., Business Centrum Zalesi, Building A2, Pod Visnovkou 1661/31, 140 00 Praha 4 – Krc, Czech Republic, registered in the Commercial Register maintained by the Municipal Court in Prague, section C., Insert: 130938, company identification number: 281 78 777, Tax Id.: CZ28178777, represented by , (hereinafter referred to as “Chiltern”); and FAKULTNÍ NEMOCNICE OLOMOUC, I.P.Pavlova 185/6, 77900 Olomouc, Czech Republic, ID No.: 00098892, Tax ID No.: CZ00098892, Represented by, director (hereinafter referred to as “Institution”) Whereas, Chiltern and Institution are hereinafter referred to individually as “Party” and collectively as “Parties”; Whereas, Chiltern is acting in its capacity as a contract research organization as defined in ICH-GCP 1.20 as an independent contractor of Boston Biomedical, Inc. (“Sponsor”) to assist Sponsor in conductin
INSTITUTION CLINICAL TRIAL AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍInstitution Clinical Trial Agreement • February 3rd, 2022
This Clinical Trial Agreement (“Agreement”) valid as of the last date of signature and effective as of the date of publication in the Contracts Register (“Effective Date”) by and among:
INSTITUTION CLINICAL TRIAL AGREEMENTInstitution Clinical Trial Agreement • April 29th, 2019
This Clinical Trial Agreement (“Agreement”) shall become effective on the day of its publication in the Contract Registry (“Effective Date”) and is made by and among:
ContractInstitution Clinical Trial Agreement • August 31st, 2023
INSTITUTION CLINICAL TRIAL AGREEMENT This Clinical Trial Agreement (“Agreement”) valid as of the last signature and effective as of the date of publication in the Registry of Contracts (“Effective Date”) by and among: Fortrea Inc., with its registered office at 10 Moore Drive, Durham, NC, 27709, USA, represented by XXX, and its affiliates (hereinafter referred to as “Fortrea” or “CRO”); and Fakultní nemocnice Bulovka, with its registered office in: Budínova 67/2 Prague 8 – Libeň, zipcode 180 81, Czech RepublicRepresented by XXXCompany ID: 00064211, Tax ID: CZ00064211Bank account: 16231081 / 0710 Česká národní bankaSWIFT: CNBACZPPvariable symbol: XXX(hereinafter referred to as “Institution”) Whereas, Fortrea and Institution are hereinafter referred to individually as “Party” and collectively as “Parties”; Whereas, Fortrea is acting in its capacity as a contract research organization as defined in ICH- GCP 1.20 as an independent contractor of ASTRAZENECA AB, 151 85 Södertälje, Sweden and
ContractInstitution Clinical Trial Agreement • November 28th, 2016
INSTITUTION CLINICAL TRIAL AGREEMENT This Clinical Trial Agreement (“Agreement”) is made on (“Effective Date”) by andamong: Chiltern International s.r.o., Business Centrum Zalesi Building A2, Pod Visnovkou 1661/31, 140 00 Praha 4 – Krc, Czech Republic, registered in the Commercial Register maintained by the Municipal Court in Prague, section C., Insert: 130938, company identification number: 281 78 777, tax Id: CZ281 78 777, represented by Dariusz Walach, MD (hereinafter referred to as “Chiltern”); and Krajská zdravotní a.s.- Masarykova nemocnice v Ústí nad Labem o.z., Sociální péče 3316/12A401 13 Ústí nad Labem, Czech Republic, registered in the Commercial Register maintained by the County Court in Ústí nad Labem, section B, Insert: 1550, company identification number: 25488627, tax Id: CZ25488627, represented by Ing. Petr Fiala, director, (hereinafter referred to as “Institution”) Whereas, Chiltern and Institution are hereinafter referred to individually as “Party” and collectively a
